GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Ado-trastuzumab emtansine (KADCYLA)

Local RX List renal extractBase record retrieved 2026-09-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

KADCYLA

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Severe impairment: label evidence gap versus eviQ full-dose guidance

The label mirror cannot recommend a dose below CrCl 30. The metastatic breast eviQ protocol permits full dose in severe indexed-eGFR bands, including below 15 without KRT. This is both an evidence-position difference and a renal-measure difference.

Before applying: Reconcile oncology indication, treatment intent, renal measure and KRT with oncology/nephrology. Do not describe eviQ as filling the label gap through proven independent trials.

Also check: Severe impairment: label evidence gap versus eviQ full-dose guidance

Rxlist source

GlobalRPh RX List - KADCYLA

Product / population
Intravenous ado-trastuzumab emtansine; not trastuzumab or trastuzumab deruxtecan.
Renal measure
CrCl in mL/min, as printed; estimator not specified in selected section.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

No dose adjustment is required for mild impairment (CrCl 60-89) or moderate impairment (30-59). The source cannot recommend a dose for severe impairment (CrCl <30) because evidence is limited. This is an evidence gap, not a no-adjustment recommendation below 30 or during dialysis.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/kadcyla-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - KADCYLA

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Intravenous ado-trastuzumab emtansine; not trastuzumab or trastuzumab deruxtecan.

Renal method: CrCl in mL/min, as printed; estimator not specified in selected section.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
Professional guidance

eviQ metastatic breast trastuzumab emtansine - kidney guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Australian metastatic breast cancer protocol; institutional/consensus-derived perspective, not a U.S. label replacement.

Renal method: Indexed eGFR mL/min/1.73 m2; kidney replacement therapy considered separately.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

professional protocol difference

Severe impairment: label evidence gap versus eviQ full-dose guidance

The label mirror cannot recommend a dose below CrCl 30. The metastatic breast eviQ protocol permits full dose in severe indexed-eGFR bands, including below 15 without KRT. This is both an evidence-position difference and a renal-measure difference.

How to use this: Reconcile oncology indication, treatment intent, renal measure and KRT with oncology/nephrology. Do not describe eviQ as filling the label gap through proven independent trials.

GlobalRPh RX List - KADCYLAeviQ metastatic breast trastuzumab emtansine - kidney guidance

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - KADCYLAeviQ metastatic breast trastuzumab emtansine - kidney guidance
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/kadcyla-drug/

Exact product and population

Intravenous ado-trastuzumab emtansine; not trastuzumab or trastuzumab deruxtecan.

RDM42-SCOPE-ado-trastuzumab-emtansine-kadcyla · Source section: Selected source product scopeRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - KADCYLA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Intravenous ado-trastuzumab emtansine; not trastuzumab or trastuzumab deruxtecan.

Renal method: CrCl in mL/min, as printed; estimator not specified in selected section.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

No dose adjustment is required for mild impairment (CrCl 60-89) or moderate impairment (30-59). The source cannot recommend a dose for severe impairment (CrCl <30) because evidence is limited. This is an evidence gap, not a no-adjustment recommendation below 30 or during dialysis.

RDM42-rxlist-ado-trastuzumab-emtansine-kadcyla-dbafed73b5-C1 · Source locator: Dosage / Renal impairment / relevant warnings

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/kadcyla-drug/
Retrieved
2026-09-07
Renal-function method
CrCl in mL/min, as printed; estimator not specified in selected section.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
aac7563c46e531cad795b9576da5977221b3b051be51ca1d0d341633acbf7d21
Separate professional-source layer

University and professional protocols

Professional

eviQ metastatic breast trastuzumab emtansine - kidney guidance

Open original reference

Open / share this exact local source

eviQ / Cancer Institute NSW · Australian metastatic breast cancer protocol; institutional/consensus-derived perspective, not a U.S. label replacement.

Renal method: Indexed eGFR mL/min/1.73 m2; kidney replacement therapy considered separately.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The protocol permits the full regimen dose for eGFR >=60, 45-59, 30-44, 15-29 and <15 without kidney replacement therapy. In kidney replacement therapy it calls for multidisciplinary oncology/nephrology or clinical-pharmacology consultation. Consider treatment intent before adjusting or omitting therapy. This contrasts with the RX label mirror, which cannot recommend a dose for CrCl <30 because of limited data. The two renal measures are not interchangeable.

RDM42-professional-ado-trastuzumab-emtansine-kadcyla-267be0f9aa-C1 · Source locator: Kidney dosing recommendations and KRT footnote

Source identity and provenance
Source family
professional_guidance
Source
https://www.eviq.org.au/medical-oncology/breast/metastatic/1598-breast-metastatic-trastuzumab-emtansine
Retrieved
2026-09-07
Renal-function method
Indexed eGFR mL/min/1.73 m2; kidney replacement therapy considered separately.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
7d9cc86f7446d2ab115b317a8b9a07767762ee290714db2948af3a68840f6d81

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/kadcyla-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
838695b6c2caec75fa7dcde7f3dd34637b7fd5cbde16f8ce05e76a90f7ae0ddb
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report